일리노이의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 31개가 일리노이 내 여러 지역에서 참여자를 모집하고 있습니다.
일리노이의 도시
- Chicago연구 22개
- Cicero연구 6개
- Evanston연구 4개
- Waukegan연구 4개
- Springfield연구 4개
- Galesburg연구 3개
- Peoria연구 3개
- Bloomington연구 3개
- Aurora연구 3개
- North Peoria연구 3개
- Decatur연구 3개
공식 연구 텍스트(영어)
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- 외 13개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06948084A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- University of Chicago Medical Center /ID# 278863, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chicago
- Research Site, Park Ridge
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Chicago Medical Center, Chicago
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University Of Illinois Medical Center, Chicago
- Loyola University Medical Center, Maywood
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Chicago, Zion
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07258511A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Northwestern University, Chicago
- University of Chicago, Chicago
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05201781A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Rush University System for Health, Chicago
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07518186Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05789303TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Chicago, Chicago
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06297226Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- University of Illinois at Chicago, Chicago
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT05344833MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Endeavor Health - Swedish Hospital, Chicago
- Endeavor Health - Evanston Hospital, Evanston
- Endeavor Health - Glenbrook Hospital Ambulatory Care Center, Glenview
- 외 6개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- 외 40개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Chicago
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chicago
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Loyola University Medical Center, Maywood
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 12. 업데이트됨 · NCT07280013Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06960993Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
- Loyola University Chicago, Maywood
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 7. 22. 업데이트됨 · NCT07236502A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Hope And Healing Cancer Services /ID# 268536, Hinsdale
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT05650632Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
피험자 모집 중관찰 연구건강한 지원자 환영
19세 ~ 110세 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT02012699Personalized Autologous Transplant for Multiple Myeloma
- University Illinois Chicago, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 15. 업데이트됨 · NCT04483206Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Anthony's Health, Alton
- Rush - Copley Medical Center, Aurora
- Saint Joseph Medical Center, Bloomington
- 외 41개
피험자 모집 중3상
전 연령 · 모든 성별 · 2026. 6. 10. 업데이트됨 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT05243797Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
피험자 모집 중1상
13세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04771572Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- University of Chicago Medical Center, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 1. 업데이트됨 · NCT05862012Hypofractionation (Radiation) Trial for Multiple Myeloma
- The University of Chicago Comprehensive Cancer Center, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 30. 업데이트됨 · NCT06270888A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 2. 23. 업데이트됨 · NCT05974150A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- City of Hope at Chicago, Zion
피험자 모집 중관찰 연구건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 2. 20. 업데이트됨 · NCT07225738Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
- University of Illinois Cancer Center, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 12. 18. 업데이트됨 · NCT05192122ClinicalTrials.gov 출처, 2026. 10. 2. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.